CYSLTR1 and prostate carcinoma: Treatment with montelukast downregulated CysLT1R expression, reduced cell viability and induced early apoptosis in human prostate cancer cell lines (LNCaP, PC3, DU-145) [64,67], a human renal cell carcinoma cell line (Caki-1) [64,68], a human bladder cancer cell line (T24) [64,65] and a testicular cancer cell line (NEC-8) [64,66].